Compare iShares Core S&P 500 ETF (IVV) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core S&P 500 ETF vs Repligen Corporation Common Stock — how do they compare? iShares Core S&P 500 ETF trades at $770.84 (market cap $896.46B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: iShares Core S&P 500 ETF is far larger — about 79.3× Repligen Corporation Common Stock's market cap, and iShares Core S&P 500 ETF is more actively traded (4,999,099 versus 1,216,919). Which is the better fit depends on your goals — on Pluang, investors hold iShares Core S&P 500 ETF for 46 Days and Repligen Corporation Common Stock for 0 Days on average.
| IVV | RGEN | |
|---|---|---|
Market Cap | $896.46B | $11.31B |
Volume | 4,999,099 | 1,216,919 |
Sector | Broad Market / Factor | Health |
52-Week High | $782.58 | $194.57 |
52-Week Low | $634.93 | $102.87 |
Typical Hold Time | 46 Days | 0 Days |
Enterprise Value | — | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IVV, tracking the S&P 500, trades at $781.42 with minimal daily change. Technical analysis shows a bullish trend with strong moving average support, though RSI indicates potential overbought conditions near-term. The ETF benefits from broad market exposure amid expectations of continued corporate profit growth, with S&P 500 earnings projected to rise 35% in 2026 according to 24/7 Wall Street on October 3, 2026.
Outlook remains positive given historical seasonal trends and strong institutional support, but risks include concentration in top holdings and potential profit growth deceleration. The ETF's low-cost structure and diversification provide stability, though market volatility and economic shifts could challenge near-term performance.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
